Research & Development
Camurus' FDA accepts CAM2029 NDA resubmission for acromegaly, sets December decision date
17 July 2026 - Swedish biopharmaceutical company Camurus AB (STO:CAMX) said on Friday that the US Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application for CA...
Vanda Pharmaceuticals reports positive EMA opinion on orphan drug designation for imsidolimab in generalised pustular psoriasis
17 July 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Thursday that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopt...
World Health Organization approves 'codabakalner' as International Nonproprietary Name for Spinogenix's SPG601
17 July 2026 - Clinical-stage biopharmaceutical company Spinogenix Inc announced on Thursday that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization has app...
Lakewood-Amedex Biotherapeutics reports positive Nu-3 Gel preclinical safety data for upcoming Phase 2a trial
16 July 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) on Wednesday announced preclinical safety data for its Nu-3 gel formulation that establishes a str...
MAXONA Pharmaceuticals' Phase 2 clinical trial IND application for MAX-001 cleared by US FDA
16 July 2026 - Clinical-stage pharmaceutical company MAXONA Pharmaceuticals announced on Wednesday that the US Food and Drug Administration (FDA) has cleared the company's Investigational New Dru...
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
15 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority re...